RxDoctor Payments Data

Katherine Argote

Physician Assistant · New Orleans, LANPI 1487125613

Payments from drug & device makers

$2,349in general payments, 2019–2025

Across 66 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$703
  • UCB, Inc.$588
  • Biohaven Pharmaceutical Holding Company Ltd.$335
  • Pfizer$173
  • AstraZeneca$160
  • Neurelis, Inc.$159
  • plus $231 from 3 others

What the payments were for

  • Food & beverage$2,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,349 in reported general payments places this provider in the 80th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$9,769
Medicare patients
61
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant17$21,041
EliquisApixaban26$14,901
Oxcarbazepine52$2,760
Levetiracetam91$2,008
Gabapentin103$1,485
Atorvastatin Calcium122$962
Lacosamide22$781
Baclofen23$711
Donepezil Hcl95$568
Memantine Hcl34$540
Topiramate53$466
Doxepin Hcl19$392
Carbidopa-LevodopaCarbidopa/Levodopa29$374
Divalproex Sodium25$367
AmantadineAmantadine Hcl12$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$703$21,04117 claims
PfizerEliquis$173$14,90126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →